Lexicon Pharmaceuticals, Inc. (LXRX)
| Market Cap | 787.57M +63.0% |
| Revenue (ttm) | 38.54M -45.6% |
| Net Income | -62.35M |
| EPS | -0.15 |
| Shares Out | 444.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,598,085 |
| Open | 1.660 |
| Previous Close | 1.610 |
| Day's Range | 1.610 - 1.840 |
| 52-Week Range | 1.100 - 2.680 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 4.47 (+152.26%) |
| Earnings Date | Nov 5, 2026 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart fail... [Read more]
Financial Performance
In 2025, Lexicon Pharmaceuticals's revenue was $49.80 million, an increase of 60.24% compared to the previous year's $31.08 million. Losses were -$50.34 million, -74.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price target is $4.47, which is an increase of 152.26% from the latest price.
News
Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2026
SONATA-HCM topline data and the ZYNQUISTA NDA resubmission are both targeted for Q1 2027. Q3 revenue was $11.3M, with $183.2M in cash equivalents and short-term investments at quarter-end.
Lexicon Pharmaceuticals Earnings release: Q3 2026
Lexicon Pharmaceuticals released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Lexicon Pharmaceuticals Slides: Q3 2026
Lexicon Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Lexicon Pharmaceuticals Quarterly report: Q3 2026
Lexicon Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 5, 2026.
Lexicon reports Q3 EPS (3c), consensus (5c)
Reports Q3 revenue $11.25M, consensus $4.14M. “This quarter brought Lexicon (LXRX) into sharper focus as a cardiometabolic company and has positioned us to approach 2027 with strong momentum and multi...
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical develo...
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its ...
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entr...
Lexicon highlights findings from sotagliflozin studies
Lexicon (LXRX) highlighted findings from two newly reported preclinical studies that provide additional insight into the biological effects of sotagliflozin, Lexicon’s dual SGLT1 and SGLT2 inhibitor. ...
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotaglif...
Lexicon initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Lexicon (LXRX) with an Overweight rating and $8 price target The firm’s thesis centers on confidence that sotagliflozin’s fully enrolled...
Lexicon initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Lexicon (LXRX) with an Overweight rating and $8 price target
Lexicon Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is advancing late-stage programs for sotagliflozin in HCM and type 1 diabetes, with key trials fully enrolled and top-line data expected in Q1 2027. Partnerships, milestone payments, and pre-commercialization activities are accelerating, positioning the pipeline for major regulatory and commercial milestones.
Lexicon Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Focused on cardiometabolic diseases, the company is advancing sotagliflozin in HCM with phase III data expected in Q1, supported by a pragmatic trial design and strong FDA alignment. Regulatory progress in type 1 diabetes and strategic partnerships in obesity and neuropathic pain enhance growth prospects.
Lexicon Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
The summit highlighted upcoming SONATA-HCM phase III data in Q1 2027, with strong commercial focus on HCM and T1D. Regulatory progress includes meeting FDA requirements for SOTA in T1D, with resubmission planned for Q4. Partnerships and AI initiatives aim to maximize pipeline value.
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking...
Lexicon announces results from post hoc analysis of SOLOIST-WHF trial
Lexicon (LXRX) announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure…
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851
Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient dosing milestone in the ongoing Phase…
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon reports Q2 EPS (7c), consensus (5c)
Reports Q2 revenue $680,000, consensus $4M. “Lexicon (LXRX) continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to…
Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2026
Enrollment in the SONATA-HCM phase III trial was completed with over-enrollment, and top-line data are expected in Q1 2027. ZYNQUISTA's NDA resubmission is planned for Q4 2026, pending final STENO-1 data. Financial flexibility improved with a new debt facility and strong cash position.
Lexicon Pharmaceuticals Earnings release: Q2 2026
Lexicon Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Lexicon Pharmaceuticals Slides: Q2 2026
Lexicon Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Lexicon Pharmaceuticals Quarterly report: Q2 2026
Lexicon Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.